Immix reported an 89% complete response rate across 45 patients and has $340.9 million in cash, expected to last into mid-2028. Its $15.9 million in quarterly operating expenses and planned 2027 FDA application show costs and work remain, but the patient results and cash support a favorable read.
The patient results strengthen the case for Immix's treatment, but they do not mean it is approved. Its cash can fund continued development and launch preparation. The company also reported $15.9 million in operating expenses for the quarter and plans to apply to the FDA in mid-2027.
Follow Immix Biopharma, Inc. (IMMX) free. When we publish a story about it, you get the plain-English explanation as an alert.
Get alerts for IMMX